Pneumococcal community-acquired pneumonia in hospitalized adults in México 2018–2021: serotype distribution and clinical characteristics

Authors:

Abstract
Background: Community-acquired pneumonia (CAP) in adults represents a significant burden on the healthcare system in México, particularly among high-risk groups. Materials and methods: Adults hospitalized with chest X-ray-confirmed CAP (2018–2021) were prospectively enrolled across four cities in México (Mexico City, Durango, Mérida, and Tijuana). Urine samples were screened for Streptococcus pneumoniae ( S. pneumoniae ) using the BinaxNOW ® test and serotype-specific urine antigen detection (ssUAD) assays targeting 24 serotypes, and blood was obtained for pneumococcal culture. Results: Of the 1,275 patients screened for CAP, 389 had clinically or radiologically confirmed CAP (65.3% male; median age, 60 years; 39.3% aged ≥65 years). Pneumococcal CAP (pCAP) was identified in 12.1% of patients (47/389; 95% CI: 9.01–15.74). Based on CRB-65 scores, pCAP was more frequent among high-risk CAP patients (25.5%, 12/47) than among low- or moderate-risk CAP patients (10.2%, 35/342). Nevertheless, the 30-day mortality rate was 34.0% among pCAP patients versus 29.5% among S. pneumoniae -negative CAP patients. The most prevalent serotypes were 3 (13.0%), 6A (8.7%), and 19A (8.7%), and PCV20 would have covered 54.3% (25/46) of pCAP serotypes identified in this study. Conclusion: During the study period, CAP was associated with a substantial mortality burden among hospitalized adult patients in México, with pCAP more frequent among high-risk patients. These findings underscore the needs for enhanced diagnostic approaches and risk group-targeted adult pneumococcal vaccination programs.
Funding Information
  • Pfizer

This publication has 39 references indexed in Scilit: